指南与共识毛发、甲与色素性疾病

低剂量口服米诺地尔治疗脱发的国际改良德尔菲共识声明

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement.
指南 / 共识 · JAMA Dermatol · 2025-01-01

该共识针对低剂量口服米诺地尔(LDOM)超说明书治疗脱发,由12个国家43名脱发专科皮肤科医生参与改良德尔菲流程,经4轮问卷就76个条目达成共识,涵盖适应症、成人及青少年剂量、禁忌、监测等;儿童(<12岁)剂量及滴定方案未达共识。

要点

  • LDOM可用于多种脱发的直接或支持性治疗,具体诊断见共识条目。
  • 成人及12-17岁青少年剂量已达成共识,但<12岁儿童剂量及滴定方案未达共识。
  • 共识涵盖基线评估、监测、辅助治疗及专科会诊建议。

核心结论

  • 该国际专家共识可为LDOM超说明书治疗脱发的临床实践提供指导,直至更多数据出现。

研究设计与样本

  • 改良德尔菲共识流程,43名来自12个国家的脱发专科皮肤科医生参与,共4轮问卷。
  • 共识定义为在5点Likert量表上至少70%同意或强烈同意。

主要发现

  • 4轮问卷分别考虑并修订180、121、16、11个条目。
  • 共76个条目达成共识,涵盖LDOM可能提供直接或支持性获益的诊断、与局部米诺地尔相比的适应症、成人(18岁及以上)和青少年(12-17岁)剂量、禁忌症、注意事项、基线评估、监测、辅助治疗及专科会诊。
  • 儿童(<12岁)使用和剂量条目及LDOM滴定方案未达共识。

关键数值与推荐

  • 共识阈值:至少70%同意或强烈同意(5点Likert量表)。
  • 达成共识的76个条目包括成人(18岁及以上)和青少年(12-17岁)的LDOM剂量。
  • 未达共识的条目包括儿童(<12岁)使用和剂量及LDOM滴定方案。

临床怎么用

  • 皮肤科医生可参考该共识进行LDOM超说明书处方,涵盖适应症、剂量、禁忌、监测等。
  • 对12-17岁青少年可依据共识剂量使用,对<12岁儿童缺乏共识。

局限性

  • 专家小组中治疗儿童患者的脱发专家代表性不足。
  • 需进一步研究儿童LDOM使用的最佳实践、局部与口服米诺地尔疗效比较、对局部米诺地尔过敏接触性皮炎患者的安全性、长期安全性及其他超说明书剂型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking. OBJECTIVE: To create an expert consensus statement for LDOM prescribing for patients with hair loss. EVIDENCE REVIEW: The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale. FINDINGS: Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus. CONCLUSIONS AND RELEVANCE: This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Akiska YM, Mirmirani P, Roseborough I, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatol. 2025. PMID: 39565602. doi:10.1001/jamadermatol.2024.4593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。